Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathalie Labarrière

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Bulletin De L'Academie Nationale De Medecine|August 13, 2015
[Melanoma: Cellular and vaccinal immunotherapy]Brigitte Dréno, Amir Khammari, Anne Chantal Knol, et al.
Medecine Sciences : M/S|July 3, 2003
[Adoptive immunotherapy in solid tumors: new hope]Francine Jotereau, Nathalie Labarrière, Nadine Gervois, et al.
Melanoma Research|May 14, 2015
A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigensBenjamin Chalopin, Laetitia Florenceau, Delphine Fradin, et al.
Cancer Immunology, Immunotherapy : CII|July 25, 2007
PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sortingNathalie Labarrière, Nadine Gervois, Annabelle Bonnin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesionBoris Linard, Stéphane Bézieau, Houssem Benlalam, et al.
European Journal of Immunology|March 11, 2010
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapyYann Godet, Juliette Desfrançois, Virginie Vignard, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2002
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patientsNathalie Labarrière, Marie-Christine Pandolfino, Nadine Gervois, et al.
European Journal of Immunology|January 31, 2003
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigensLydie Trautmann, Nathalie Labarrière, Francine Jotereau, et al.
Cancer Immunology, Immunotherapy : CII|August 30, 2008
A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytesRégis Bouquié, Annabelle Bonnin, Karine Bernardeau, et al.
Oncoimmunology|July 3, 2026
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancerMathilde Deiber, Cécile Deleine, Nadine Gervois-Segain, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Bulletin De L'Academie Nationale De Medecine|August 13, 2015
[Melanoma: Cellular and vaccinal immunotherapy]Brigitte Dréno, Amir Khammari, Anne Chantal Knol, et al.
Medecine Sciences : M/S|July 3, 2003
[Adoptive immunotherapy in solid tumors: new hope]Francine Jotereau, Nathalie Labarrière, Nadine Gervois, et al.
Melanoma Research|May 14, 2015
A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigensBenjamin Chalopin, Laetitia Florenceau, Delphine Fradin, et al.
Cancer Immunology, Immunotherapy : CII|July 25, 2007
PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sortingNathalie Labarrière, Nadine Gervois, Annabelle Bonnin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 24, 2002
A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesionBoris Linard, Stéphane Bézieau, Houssem Benlalam, et al.
European Journal of Immunology|March 11, 2010
Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapyYann Godet, Juliette Desfrançois, Virginie Vignard, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2002
Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patientsNathalie Labarrière, Marie-Christine Pandolfino, Nadine Gervois, et al.
European Journal of Immunology|January 31, 2003
Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigensLydie Trautmann, Nathalie Labarrière, Francine Jotereau, et al.
Cancer Immunology, Immunotherapy : CII|August 30, 2008
A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytesRégis Bouquié, Annabelle Bonnin, Karine Bernardeau, et al.
Oncoimmunology|July 3, 2026
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancerMathilde Deiber, Cécile Deleine, Nadine Gervois-Segain, et al.
Pageof 5